Organism: Homo sapiens
Gene: 38740_at
Selected probe(set): 211962_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38740_at (211962_s_at) across 6672 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):7.234743
Number of Samples:3 / 2

Experimental	PMA study 2
	MONO-MAC-6 (MM6) cells were treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:---
Control	mock treated MONO-MAC-6 cell sample
	MONO-MAC-6 (MM6) cells mock treated.

Relative Expression (log2-ratio):6.567232
Number of Samples:2 / 2

Experimental	LPS study 4
	MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control	mock treated MONO-MAC-6 cell sample
	MONO-MAC-6 (MM6) cells mock treated.

Relative Expression (log2-ratio):6.474964
Number of Samples:3 / 2

Experimental	PMA study 2 (shRNA contr.)
	MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:---
Control	mock treated / transduced MONO-MAC-6 cell sample
	MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated.

Relative Expression (log2-ratio):5.6622496
Number of Samples:2 / 2

Experimental	LPS study 4 (shRNA contr.)
	MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control	mock treated / transduced MONO-MAC-6 cell sample
	MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated.

Relative Expression (log2-ratio):5.303565
Number of Samples:3 / 2

Experimental	PMA study 2 (shRNA cycT1)
	MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:---
Control	cycT1 depletion study 2 (shRNA)
	MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated.

Relative Expression (log2-ratio):4.273983
Number of Samples:2 / 2

Experimental	LPS study 4 (shRNA cycT1)
	MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control	cycT1 depletion study 2 (shRNA)
	MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated.

Relative Expression (log2-ratio):3.7555199
Number of Samples:2 / 2

Experimental	PMA study 3 (shRNA contr.)
	Jurkat cells were transduced with a control shRNA and then treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:---
Control	mock treated / transduced Jurkat cell sample
	Jurkat cells were transduced with a control shRNA and then mock treated.

Relative Expression (log2-ratio):3.4390125
Number of Samples:2 / 2

Experimental	PMA study 3 (shRNA cycT1)
	Jurkat cells were transduced with shRNA against cyclin T1 and then treated with 10ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:---
Control	cycT1 depletion study 1 (shRNA)
	Jurkat cells were transduced with shRNA against cyclin T1 and then mock treated.

Relative Expression (log2-ratio):3.273305
Number of Samples:4 / 2

Experimental	glioma study 27 (glioblastoma, NOS)
	Primary tumor samples from resected brain tissues of patients with glioblastoma, NOS(WHO grade IV astrocytoma).
Control	glioma study 27 (pilocytic astrocytoma)
	Primary tumor samples from resected brain tissues of patients with pilocytic astrocytoma (WHO grade I astrocytoma).

Relative Expression (log2-ratio):-3.2615175
Number of Samples:4 / 4

Experimental	stem cell differentiation study 59 (iDRG; 12d)
	Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 4 days. Further details are described in the paper.
Control	stem cell differentiation study 59 (8d)
	WA09 embryonic stem cell samples differentiated for 8 days. Further details are described in the paper.